Time to Take Sleeping Pills and Subjective Satisfaction among Cancer Patients

Soyoung Youn,Byeongil Choi,Suyeon Lee,Changnam Kim,Seockhoon Chung 대한신경정신의학회 2020 PSYCHIATRY INVESTIGATION Vol.17 No.3

Objective We investigated the influence of the time to take hypnotics and daytime activity on patient satisfaction with sleeping pills. Methods Ninety-six cancer patients who were currently taking benzodiazepine or z-drug as hypnotics were grouped into satisfied and dissatisfied groups. The subjects’ symptoms, time to take sleeping pills, bedtime, sleep onset time, wake up time, and time in bed within 24 hours (TIB/d) were obtained. Results The satisfied group had significantly late sleeping pill ingestion time (p=0.04); significantly early wake up time (p=0.01); and significantly shorter sleep latency, TIB/d, duration from the administration of pills to sleep onset, and duration from the administration of pills to wake up time (PTW). Logistic regression analysis revealed that the significant predictors of patient satisfaction to hypnotics were less severity of insomnia [odds ratio (OR)=0.91] and the time variables, including late sleeping pill administration time (OR=1.53) and early wake up time (OR=0.57). Among the duration variables, short PTW (OR=0.30) and short TIB/d (OR=0.64) were significantly related with the satisfaction to hypnotics. Conclusion Reducing the duration from the administration of hypnotics to wake up time and TIB/d can influence the satisfaction to sleeping pills.

Progression of cognitive impairments in idiopathic REM sleep behaviour disorder

Youn, Soyoung,Kim, Tae,Yoon, In-Young,Jeong, Jahyun,Kim, Hye Young,Han, Ji Won,Kim, Jong-Min,Kim, Ki Woong British Medical Association 2016 Journal of neurology, neurosurgery and psychiatry Vol.87 No.8

<P>Background Idiopathic REM (rapid eye movement) sleep behaviour disorder (iRBD) has been implicated in cognitive impairments, but there is little evidence about progression of cognitive dysfunction in iRBD. Methods A retrospective follow-up study with patients with iRBD was performed. Conversion to neurodegenerative disorders was analysed by Kaplan-Meier survival analysis. Neuropsychological test results at baseline were compared between patients with iRBD and healthy controls. 57 patients with iRBD were successfully followed up for changes of cognitive performance over time (follow-up duration 50.84 +/- 25.38 months; range 12-108 months). Factors affecting cognitive decline were evaluated with multiple regression analysis and the subgroup analysis for groups with and without conversion was carried out. Results Among 84 patients with iRBD, conversion occurred in 18 patients and conversion rates were estimated to be 9%, 18% and 35% at 3, 5 and 6 years from diagnosis of iRBD. Individuals with iRBD showed lower z-scores at baseline than controls in Mini-Mental Status Examination, Trail Making Test A, constructional praxis and Executive Clock Drawing Task (CLOX2). Patients with non-converting iRBD showed significant performance decline in memory (p=0.003, Digit span forward) and a worsening tendency of executive functions (p=0.007, frontal assessment battery; p=0.012, Stroop test) at follow-up tests. Cognitive decline was associated with disease duration or follow-up duration, and lower executive function at baseline increased conversion risk (p=0.031). Conclusions Patients with iRBD have cognitive impairments at baseline and progressive cognitive decline over time. Even in idiopathic cases without development of any neurodegenerative disease, degenerative changes in cognition seem to be under way.</P>

The Effect of a Sleep Education and Hypnotics Reduction Program on Hypnotics Prescription Rate for the Hospitalized Patients with Cancer at a General Hospital

Soyoung Youn,Su-yeon Lee,Changnam Kim,Seockhoon Chung 대한정신약물학회 2019 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.17 No.4

Objective: We aimed to investigate whether the sleep education and hypnotics reduction program (the i-sleep program), developed for all hospitalized patients and medical personnel, help reducing the hypnotics prescriptions rate among hospitalized cancer patients in a general hospital. Methods: Patient data such as hypnotics prescribed at the time of admission and discharge during prior to (year of 2014) and after (year of 2015) initiation of the i-sleep program were collected and compared. Also, hypnotics prescription rate at the first day of each month of 2014 and 2015 were estimated and compared. Results: All of 12,382 patients in 2014 and 12,313 patients in 2015 were admitted to the Department of Oncology of the hospital. In 2014, 782 (6.3%) of 12,382 inpatients were already taking hypnotics at the time of admission, and 594 (76.0%) of the 782 patients were still taking sleeping pills at the time of discharge. Following initiation of the i-sleep program (2015), 792 (6.4%) of 12,313 inpatients were already taking hypnotics at the time of admission, and 553 (69.8%) of the 792 inpatients were still taking them at the time of discharge (relative risk, 0.92; 95% confidence interval, 0.87−0.98). On the first day of each month of 2014, 7.3% to 12.6% (mean, 10.0%) of inpatients had prescriptions for hypnotics. Following initiation of the program, the rate of hypnotic prescription was significantly reduced (3.2−10.8%; mean, 8.0%; p = 0.03). Conclusion: Our date showed that the i-sleep program may help to reduce the hypnotic prescription rate in hospitalized cancer patients.

Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet

Lee, Soyoung,Nam, Kyu-Yeol,Oh, Jaeseong,Lee, SeungHwan,Cho, Sang-Min,Choi, Youn-Woong,Cho, Joo-Youn,Lee, Beom-Jin,Hong, Jang Hee Dove Medical Press 2018 Drug design, development and therapy Vol.12 No.-

<P><B>Background</B></P><P>Levodropropizine is a non-opioid antitussive agent that inhibits cough reflex by reducing the release of sensory peptide in the peripheral region. To improve patients’ compliance, a controlled-release (CR) tablet is under development. The aim of this study was to compare the pharmacokinetic (PK) profiles of the CR and immediate-release (IR) tablets of levodropropizine. In addition, the effect of food on the PK properties of levodropropizine CR tablet in healthy subjects was evaluated.</P><P><B>Subjects and methods</B></P><P>A randomized, open-label, multiple-dose, three-treatment, three-period, six-sequence, crossover study was conducted on 47 healthy subjects. All subjects were randomly assigned to one of the six sequences, which involve combinations of the following three treatments: levodropropizine IR 60 mg three times in the fasted state (R), levodropropizine CR 90 mg two times in the fasted state (T), and levodropropizine CR 90 mg two times in the fed state (TF). Serial blood samples were collected up to 24 h after the first dose. Tolerability was assessed based on the vital signs, adverse events (AEs), and clinical laboratory tests.</P><P><B>Results</B></P><P>Levodropropizine CR showed lower maximum drug concentration (<I>C</I><SUB>max</SUB>) and similar total exposure compared to levodropropizine IR. The geometric mean ratios (GMRs) (90% confidence intervals [CIs]) of T to R for the <I>C</I><SUB>max</SUB> and area under the concentration–time curve from the 0 to 24 h time points (AUC<SUB>0–24h</SUB>) were 0.80 (0.75–0.85) and 0.89 (0.86–0.93), respectively. In the fed group, levodropropizine CR showed exposure similar to that in the fasted group. The GMRs (90% CIs) of TF to T for the <I>C</I><SUB>max</SUB> and AUC<SUB>0–24h</SUB> were 0.90 (0.85–0.97) and 1.10 (1.05–1.14), respectively. No serious AEs occurred with both levodropropizine CR and IR tablets.</P><P><B>Conclusion</B></P><P>Total systemic exposure for levodropropizine was similar in subjects receiving the CR and IR formulations in terms of the AUC. Although food delayed the absorption of levodropropizine CR, systemic exposure was not affected.</P>

Dysfunctional Beliefs about Sleep in Cancer Patients Can Mediate the Effect of Fear of Progression on Insomnia

Insoo Kim,Kikyoung Yi,이주희,Kyumin Kim,Soyoung Youn,서수연,Jiyeon Kim,Jung mun choi,정석훈 대한수면학회 2019 sleep medicine research Vol.10 No.2

Sleep Med Res > Volume 10(2); 2019 > Article Original Article Sleep Medicine Research (SMR) 2019; 10(2): 83-89. Published online: Dec 31, 2019 DOI: https://doi.org/10.17241/smr.2019.00451 Dysfunctional Beliefs about Sleep in Cancer Patients Can Mediate the Effect of Fear of Progression on Insomnia Insoo Kim, MD1, Kikyoung Yi, MD2, Joohee Lee, MD1, Kyumin Kim, MD1, Soyoung Youn, MD1, Sooyeon Suh, PhD3, Jiyeon Kim, PhD4, Jung Mun Choi, BA1, Seockhoon Chung, MD, PhD1 1Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 2Department of Psychiatry, Yongin Mental Health, Yongin, Korea 3Department of Psychology, Sungshin Women’s University, Seoul, Korea 4Department of Art Therapy, Hanyang Cyber University, Seoul, Korea Correspondence: Seockhoon Chung, MD, PhD, Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, 86 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea, Tel +82-2-3010-3411, Fax +82-2-485-8381, E-mail schung@amc.seoul.kr Received Oct 21, 2019 Revised Nov 1, 2019 Accepted Nov 5, 2019 Copyright© 2019 The Korean Society of Sleep Medicine Abstract Background and Objective The role of the dysfunctional belief about sleep is important for the development of insomnia among cancer patients. This study intended to investigate whether dysfunctional belief about sleep mediates the relationship between fear of progression and insomnia in cancer patients. Methods Three hundred and thirty-seven cancer patients participated in our study. Dysfunctional belief about sleep, severity of insomnia, depression, fear of progression, and anxiety were measured using the following questionnaires: Cancer-related Dysfunctional Beliefs about Sleep (C-DBS); Insomnia Severity Index (ISI); Patient Health Questionnaire-9 (PHQ-9); Fear of Progression (FoP); and the state subcategory of State and Trait Anxiety Inventory (STAI). Path analysis was used to clarify the relationships among the variables. Since C-DBS consists of two items, i.e., Q1-immune & Q2-recurrence, we implemented an additional path analysis including these variables separately. Results C-DBS mediated the effect of FoP (β = 0.36, p < 0.001) and patient sex (β = 0.13, p = 0.009) on ISI. PHQ-9 (β = 0.32, p < 0.001) and STAI (β = -0.09, p = 0.071) had a direct influence on ISI scores. In our second path analysis, Q1-immune item mediated the effect of FoP (β = 0.19, p < 0.001) on ISI, and Q2-recurrence item mediated the effect of FoP (β = 0.23, p < 0.001) and patient sex (β = 0.09, p = 0.019) on ISI. Conclusions Our path analysis model indicated that C-DBS mediates the effect of FoP and patient sex on ISI. Our second path analysis results suggested that there could be an internal process of Q1 and Q2 item. Efforts to reduce dysfunctional beliefs should be considered as well as management of fear of progression for better sleep of cancer patients.

The long-term effects of an international teaching practicum: The development of personal and professional competences of Korean pre-service teachers

Youn Ock Kim,Soyoung Yu,설양환 한국교육개발원 2021 KEDI Journal of Educational Policy Vol.18 No.1

This study investigates the long-term effects of an international teaching practicum (ITP) on the development of teachers’ personal and professional competence. Based on diaries of seven Korean participants in their ITP, the study also explores the teachers’ current experiences. Data were collected using three methods: teaching diaries, interviews from the participants, and field-notes from the program instructor. The teaching diaries were written while the participants were in their ITP (2016-2017), and the interviews were conducted in 2018. Through ITP participation, the Korean pre-service teachers achieved various insights toward differences, and this led them to possess openness. These insights became their identities-in-practice as a kind person and innovative teacher, which brought reconceptualization and reconstruction of their teaching practice, long-termly.

Simultaneous analysis of acetylcarnitine, proline, hydroxyproline, citrulline, and arginine as potential plasma biomarkers to evaluate NSAIDs-induced gastric injury by liquid chromatography–tandem mass spectrometry

Shin, Soyoung,Jeong, Hyeon Myeong,Chung, Seung Eun,Kim, Tae Hwan,Thapa, Subindra Kazi,Lee, Da Young,Song, Chang Ho,Lim, Jun Young,Cho, Sang-Min,Nam, Kyu-Yeol,Kang, Won-Ho,Choi, Youn-Woong,Shin, Beom S Elsevier 2019 Journal of Pharmaceutical and Biomedical Analysis Vol.165 No.-

<P><B>Abstract</B></P> <P>Although major adverse effects associated with nonsteroidal anti-inflammatory drugs (NSAIDs) are gastric injury, assessment of NSAIDs-induced gastrointestinal adverse effects is mostly dependent on endoscopy due to the lack of plasma biomarkers. Several amino acids associated with collagenase activity and gastric mucosal mass have been suggested as plasma biomarker candidates for gastric injury. Therefore, this study aimed to develop a liquid chromatography-tandem mass spectrometry (LC–MS/MS) method for the plasma biomarker candidates, i.e., acetylcarnitine, proline, hydroxyproline, citrulline, and arginine and evaluate their potential as a biomarker for NSAIDs-induced gastric injury. The method utilized simple protein precipitation with methanol and D<SUB>4</SUB>-citrulline as an internal standard (IS). The assay resulted in the lower limit of quantification (LLOQ) of 0.1 μg/mL for acetylcarnitine and 1 μg/mL for proline, hydroxyproline, citrulline, and arginine in the surrogate blank plasma. The intra- and inter-day accuracy ranged 82.5–111.2% for acetylcarnitine, 95.4–103.3% for proline, 98.9–106.4% for hydroxyproline, 99.5–103.5% for citrulline, and 87.4–105.3% for arginine. The precision was within 6.17%, 3.63%, 6.20%, 6.31%, and 6.17% for acetylcarnitine, proline, hydroxyproline, citrulline, and arginine, respectively. The developed assay was successfully applied to monitor the changes of the plasma levels of the five amino acids in rats and Beagle dogs following repeated oral administrations of aceclofenac. In rats, plasma concentrations of proline, hydroxyproline, and citrulline were significantly reduced after 4 days of aceclofenac administration compared to the control group. In dogs, plasma concentrations of proline and citrulline were significantly decreased after 7 days of aceclofenac administration compared to those obtained after the first aceclofenac administration. These data indicate that plasma levels of proline, hydroxyproline, and citrulline may be used as quantitative biomarkers of NSAIDs-induced gastric damage. The present assay could also be utilized to monitor the changes of these amino acids as potential indicators for various physiological and pathophysiological conditions.</P> <P><B>Highlights</B></P> <P> <UL> <LI> LC–MS/MS analysis for simultaneous determination of 5 amino acids was developed. </LI> <LI> The assay was fully validated and applied to in vivo studies in rats and dogs. </LI> <LI> Proline, hydroxyproline, and citrulline levels were reduced by aceclofenac doses. </LI> <LI> The assay may be useful to monitor changes of the amino acid levels as biomarkers. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>

Neuropsychological Tests for Patients with Marchiafava-Bignami Disease: A Case Report

HyunChul Youn,Soyoung Irene Lee,Shin-Gyeom Kim,Jeewon Lee,Han-yong Jung 대한신경정신의학회 2020 PSYCHIATRY INVESTIGATION Vol.17 No.12

커뮤니티 점유시간을 이용한 상품추천 시스템의 설계 및 구현

천소영 ( Soyoung Cheon ),윤성대 ( Sungdae Youn ) 한국정보처리학회 2004 한국정보처리학회 학술대회논문집 Vol.11 No.2

전자상거래 시장에서 고객이 관심있는 카테고리가 포괄적이고, 우선순위를 알 수 없기 때문에 이 정보를 이용하여 상품을 추천한다는 것은 고객의 개인적인 취향을 충분히 반영하지 못한다고 할 수 있다. 이에 본 논문에서는 포털사이트에 가입된 기존의 고객이 활동하고 있는 커뮤니티들 중에서 빈번히 접속하고 장시간 머물러 있는 커뮤니티를 분석해 낸다. 또한 분석된 커뮤니티 카테고리와 연관된 상품을 고객에게 추천하도록 하여 구매율을 높일 수 있는 시스템을 설계하고자 한다.

Resistin upregulates <i>MUC5AC/B</i> mucin gene expression in human airway epithelial cells

Kwak, Soyoung,Kim, Yong-Dae,Na, Hyung Gyun,Bae, Chang Hoon,Song, Si-Youn,Choi, Yoon Seok Elsevier 2018 Biochemical and biophysical research communication Vol.499 No.3

<P><B>Abstract</B></P> <P>Adipokines, a group of proteins including leptin, visfatin, resistin, and adiponectin, are produced by adipocytes. Among adipokines, resistin is implicated in insulin resistance and inflammatory response modulation. Mucus hypersecretion has been greatly linked to airway diseases, such as asthma, chronic obstructive pulmonary disease, and rhinosinusitis. Increasing evidence has indicated that adipokines, such as leptin and visfatin, play important regulatory roles in various biological processes involved in mucus secretion. However, the effects of resistin on mucin expression in human airway epithelial cells, as well as the underlying mechanisms, have not been investigated yet. We showed that resistin affected mucin expression in human airway epithelial cells <I>via</I> the mitogen-activated protein kinase/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. Resistin increased MUC5AC and MUC5B expression in NCI-H292 and primary human nasal epithelial cells. Additionally, it significantly increased the phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), p38, and NF-κB. ERK1/2 and p38 specific inhibitors significantly attenuated resistin-induced MUC5AC/5B expression; however, NF-κB inhibitor reduced resistin-induced MUC5AC, but not MUC5B, expression. Knockdown of ERK1, ERK2, and p38 by ERK1, ERK2, and p38 small interfering RNA (siRNA), respectively, significantly blocked resistin-induced MUC5AC and MUC5B mRNA expression. In addition, NF-κB siRNA attenuated resistin-induced MUC5AC, but not MUC5B, expression. These results suggested that resistin induced MUC5AC and MUC5B expression <I>via</I> activation of different signaling pathways in human airway epithelial cells.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Resistin are implicated in modulation of airway mucin secretion. </LI> <LI> Resistin induce MUC5AC and MUC5B expression. </LI> <LI> Resistin induce MUC5AC expression via ERK1/2, p38 MAPK, and NF-kB. </LI> <LI> Resistin induce MUC5B expression via ERK1/2 and p38 MAPK. </LI> </UL> </P>